ImpediMed Financials
| IPDQF Stock | USD 0.05 0.00 0.00% |
ImpediMed |
Understanding current and past ImpediMed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ImpediMed's financial statements are interrelated, with each one affecting the others. For example, an increase in ImpediMed's assets may result in an increase in income on the income statement.
ImpediMed Stock Summary
ImpediMed competes with PennantPark Investment, Algoma Steel, Titan International, Old Republic, and Insteel Industries. ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia. Impedined operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 73 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 50 Parker Court, |
| Sector | Healthcare |
| Industry | Medical Devices |
| Benchmark | Dow Jones Industrial |
| Website | www.impedimed.com |
| Phone | 61 7 3860 3700 |
| Currency | USD - US Dollar |
ImpediMed Key Financial Ratios
There are many critical financial ratios that ImpediMed's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that ImpediMed Limited reports annually and quarterly.ImpediMed Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImpediMed's current stock value. Our valuation model uses many indicators to compare ImpediMed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImpediMed competition to find correlations between indicators driving ImpediMed's intrinsic value. More Info.ImpediMed Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImpediMed's earnings, one of the primary drivers of an investment's value.ImpediMed Limited Systematic Risk
ImpediMed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ImpediMed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on ImpediMed Limited correlated with the market. If Beta is less than 0 ImpediMed generally moves in the opposite direction as compared to the market. If ImpediMed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ImpediMed Limited is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ImpediMed is generally in the same direction as the market. If Beta > 1 ImpediMed moves generally in the same direction as, but more than the movement of the benchmark.
ImpediMed December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ImpediMed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ImpediMed Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of ImpediMed Limited based on widely used predictive technical indicators. In general, we focus on analyzing ImpediMed Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ImpediMed's daily price indicators and compare them against related drivers.
| Downside Deviation | 35.03 | |||
| Information Ratio | 0.0823 | |||
| Maximum Drawdown | 179.6 | |||
| Value At Risk | (19.09) | |||
| Potential Upside | 36.74 |
Complementary Tools for ImpediMed Pink Sheet analysis
When running ImpediMed's price analysis, check to measure ImpediMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImpediMed is operating at the current time. Most of ImpediMed's value examination focuses on studying past and present price action to predict the probability of ImpediMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImpediMed's price. Additionally, you may evaluate how the addition of ImpediMed to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |